Clinical trial · Observational
The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins
Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins
NCT01341171CI-TRIAL-00047212completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- tamoxifen or aromatase inhibitors
Primary outcomes (1)
- measure
- Angiogenic Protein levels
- timeFrame
- following 6 months of therapy
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist Exclusion Criteria: * Use of heparin, warfarin
References
Publications (0)
Data not yet available
No reference posted for this study.